Literature DB >> 27882176

Effect of the interaction between atorvastatin and selective serotonin reuptake inhibitors on the blood redox equilibrium.

Mariola Herbet1, Monika Gawrońska-Grzywacz1, Magdalena Izdebska1, Iwona Piątkowska-Chmiel1.   

Abstract

Cardiovascular disease and depression often occur simultaneously in the same patient. Long-term polypharmacotherapy can lead to drug-induced oxidative stress. Data concerning the effects of concomitant treatment with atorvastatin and selective serotonin reuptake inhibitors (SSRIs) are lacking. The aim of the present study was to examine oxidative stress parameters in the blood of rats after 28 days treatment with atorvastatin combined with fluoxetine or paroxetine. The study was carried out on male Wistar rats weighing 200-250 g. Aqueous solutions of atorvastatin (10 mg/kg), fluoxetine (10 mg/kg) and paroxetine (10 mg/kg) were injected once a day for 28 days, separately or concomitantly. The activity of glutathione peroxidase (GPX) was determined in the whole blood, whereas the activity of glutathione reductase (GR) and the total antioxidant status (TAS) were determined in the serum. The results demonstrated that concomitant administration of atorvastatin with fluoxetine caused an increase in the GPX activity and the TAS. Atorvastatin administered to rats with paroxetine increased the activities of GPX and GR. In the groups of rats receiving atorvastatin or SSRIs separately, no statistically significant changes in the investigated parameters were observed. The changes that were detected may indicate an increase in endogenous antioxidant levels during the concomitant application of atorvastatin with SSRIs and thus a drug-drug interaction having an effect on the blood redox equilibrium.

Entities:  

Keywords:  atorvastatin; fluoxetine; oxidative stress parameters; paroxetine; rat

Year:  2016        PMID: 27882176      PMCID: PMC5103836          DOI: 10.3892/etm.2016.3794

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  34 in total

1.  Effects of nitric oxide synthesis inhibitor or fluoxetine treatment on depression-like state and cardiovascular changes induced by chronic variable stress in rats.

Authors:  Jeferson Almeida; Josiane O Duarte; Leandro A Oliveira; Carlos C Crestani
Journal:  Stress       Date:  2015-06-11       Impact factor: 3.493

2.  Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease.

Authors:  J C Nelson; J S Kennedy; B G Pollock; F Laghrissi-Thode; M Narayan; M S Nobler; D W Robin; I Gergel; J McCafferty; S Roose
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

3.  Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status.

Authors:  Amar Nagila; Thinnakorn Permpongpaiboon; Soontharee Tantrarongroj; Pornwalee Porapakkham; Kultira Chinwattana; Sara Deakin; Sureerut Porntadavity
Journal:  Pharmacol Rep       Date:  2009 Sep-Oct       Impact factor: 3.024

4.  Statins Decrease Oxidative Stress and ICD Therapies.

Authors:  Heather L Bloom; Irfan Shukrullah; Emir Veledar; Rebecca Gutmann; Barry London; Samuel C Dudley
Journal:  Cardiol Res Pract       Date:  2010-03-25       Impact factor: 1.866

Review 5.  Treatment of depression in patients with heart disease.

Authors:  Steven P Roose
Journal:  Biol Psychiatry       Date:  2003-08-01       Impact factor: 13.382

Review 6.  Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review.

Authors:  Meera Vaswani; Farzana Kadar Linda; Subramanyam Ramesh
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-02       Impact factor: 5.067

Review 7.  Psychological and pharmacological interventions for depression in patients with coronary artery disease.

Authors:  Harald Baumeister; Nico Hutter; Jürgen Bengel
Journal:  Cochrane Database Syst Rev       Date:  2011-09-07

8.  Drug-induced oxidative stress and toxicity.

Authors:  Damian G Deavall; Elizabeth A Martin; Judith M Horner; Ruth Roberts
Journal:  J Toxicol       Date:  2012-08-05

Review 9.  Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers.

Authors:  Xinyuan Li; Pu Fang; Jietang Mai; Eric T Choi; Hong Wang; Xiao-feng Yang
Journal:  J Hematol Oncol       Date:  2013-02-25       Impact factor: 17.388

10.  The mechanisms by which antidepressants may reduce coronary heart disease risk.

Authors:  Marc J Mathews; Edward H Mathews; Leon Liebenberg
Journal:  BMC Cardiovasc Disord       Date:  2015-08-01       Impact factor: 2.298

View more
  2 in total

1.  Radical Scavenging Potential of the Phenothiazine Scaffold: A Computational Analysis.

Authors:  Marco Dalla Tiezza; Trevor A Hamlin; F Matthias Bickelhaupt; Laura Orian
Journal:  ChemMedChem       Date:  2021-10-15       Impact factor: 3.540

2.  Fluoxetine scaffold to design tandem molecular antioxidants and green catalysts.

Authors:  Giovanni Ribaudo; Marco Bortoli; Alberto Ongaro; Erika Oselladore; Alessandra Gianoncelli; Giuseppe Zagotto; Laura Orian
Journal:  RSC Adv       Date:  2020-05-15       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.